The patient is waiting

The Prophage Series cancer vaccines extend across multiple tumor types. With every insight gained in every clinical trial, we're getting closer to fulfilling our promise to our patients. Current efforts are aimed at exploring new partners globally.

The G-Series Prophage Series in glioma

G-100 Newly Diagnosed
  • Exciting early results using Prophage G-100 Series in combination with an approved therapy, Temodar®, in newly diagnosed patients have led to expansion of the Phase 2 study
G-200 Recurrent
  • Promising monotherapy results in recurrent disease sparked additional studies
  • Immune response demonstrated

The R-Series Prophage Series in renal cell carcinoma (RCC)

R-100 Adjuvant (Oncophage)
  • International Phase 3 study completed. Statistically significant results in patients with better prognostic factors
  • Approved in Russia for patients at intermediate risk for disease recurrence
  • Phase 2 clinical study ongoing to evaluate immune response. Data could support additional international regulatory approvals
R-200 Metastatic
  • Promising efficacy signals observed in Phase 2 studies
  • Planning Phase 2 combination study with an approved therapy

The NP-Series Prophage Series in pediatric neurological tumors*

NP-150 Pediatric
  • Encouraging results in adult glioma have spurred research in pediatric brain tumors
  • Manufacturing feasibility of Prophage NP-150 from pediatric brain tumors has been demonstrated
  • Phase 1 study to be initiated in newly diagnosed and recurrent setting

The M-Series Prophage Series in melanoma

M-100 Adjuvant
  • New approaches for making the Prophage Series available from small tumors, typical of the adjuvant setting, are in the research phase
M-200 Metastatic
  • Immune response demonstrated in Phase 2 studies
  • International Phase 3 study completed using Prophage M-200 as monotherapy. Statistically significant results in patients with better prognostic factors (eg, stages M1a and M1b)
  • Preparing combination studies with immunomodulatory agents